How Immunocore tackles formulation development and delivery challenges for novel bispecifics

Bispecific biotherapeutics are a promising modality for treating cancer, HIV (Human Immunodeficiency Virus), and other autoimmune diseases.

As with any other biotherapeutic, the formulation development process is key to ensuring these drugs remain stable and active when administered to patients.

At Immunocore, Senior Scientist II, Dr Jordan Bye and his team focus on the formulation development of ImmTAX, (Immune Mobilizing Monoclonal TCRs Against X disease), potent novel bispecific molecules, so they remain stable throughout development, manufacturing, and storage until delivery.

Watch this webinar to hear from Dr. Jordan Bye, Senior Formulation Development Scientist II at Immunocore, as he shares approaches and insights into formulating these innovative therapies.

You’ll learn about:

ImmTAX – Immunocore’s proprietary T-cell bispecific molecules – and how they work
The different stability considerations for bispecific formulation development and parallels with the formulation of monoclonal antibodies
How Jordan selects optimal formulations – with data examples from the Prometheus Panta instrument for multi-parameter stability characterization Challenges related to delivery of low dose, potent bispecific therapeutics

Curious about how to use Prometheus Panta for formulation screening? Watch this video.

Previous Video

Fluorescence-Based Technologies for Binding Affinity Studies: Benefits and Labeling Best Practices

Regardless of fluorescence technology (i.e Spectral Shift, TRIC, or FRET), optimizing your labeling strateg...

Up next

Fragment Screening: Save time and sample with Spectral Shift technology

Many methods used in fragment-based drug discovery pose real challenges — SPR often struggles to detect tru...

How Immunocore tackles formulation development and delivery challenges for novel bispecifics

Previous Video

Up next

Most recent content

Regardless of fluorescence technology (i.e Spectral Shift, TRIC, or FRET), optimizing your labeling strategy is essential to minimize impact on the functionality and ensure accurate Kd measurements

Many methods used in fragment-based drug discovery pose real challenges — SPR often struggles to detect true hits due to fragments’ small mass, DSF can have high rates of false positives, and NMR equi

Get developability profiles for monoclonal antibodies with stability data from Prometheus Panta to inform on rational design and selection of therapeutic constructs that will succeed in the clinic.

Learn how to identify optimal buffer conditions during pre-formulation, with multi-parameter stability characterization from Prometheus Panta, a tool to collect thermal and colloidal data while saving

Characterize the developability of antibody-drug conjugates: Multi-parameter stability assessment with Prometheus Panta makes it possible to examine multiple aspects of ADC stability in parallel.

For antibody-drug conjugate (ADC) development, scientists rely on stability experiments using fluorescence and light scattering techniques to predict the conjugated molecule's behavior.

To understand signaling pathways, Spectral Shift technology allows for accurate bindings affinity measurements of membrane proteins like GPCRs in close to native conditions.

Transcription factors have traditionally been considered challenging therapeutic targets. Their intrinsic disorder and lack of small molecule binding pockets make them intractable to small molecule ap

MYC is an important therapeutic target that associates with MAX to regulate gene transcription. Its lack of binding pockets and the presence of disordered regions make it a difficult protein to study

Join this conversation to gain insight into how the Analytical and Formulation Sciences team at Thermo Fisher Scientific approaches stability assessment of biologic, and how the Prometheus Panta helps

To assess the developability properties of antibody-drug conjugates (ADCs) learn about multi-parameter characterization of thermal and colloidal stability with Prometheus Panta using nanoDSF and DLS

Thermal stability screening is a common approach used to study the developability of a wide range of protein-based therapeutics. Among the different technologies available to perform thermal stability

Learn about four methods for thermal stability measurements: DSC, CD, DSF and nanoDSF. You'll review their pros and cons, what they data tell you and why it's important for biologics developability.

Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl

In this video, Nathan Wallace, Application Specialist at NanoTemper, addresses common questions about experimental design for developability profiling and the operation of Prometheus Panta.

Developability assessment is a critical part of the evaluation and selection of candidates for further optimization and development for biologics researchers. This work entails collecting, ranking, an

The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co

Full developability profiles de-risk the selection process for biologics candidates during early development workflows. There are many critical quality attributes to evaluate when it comes to developa

Developability work requires the assessment of multiple critical quality attributes (CQAs) of your biologics. Many of these CQAs are measured or monitored using low-volume, low-concentration samples.

Watch this 15 min video to learn how groups in early biologics development and formulation use Dynamic Light Scattering (DLS) to make informed decisions that de-risk downstream biologics development.